A daily pill may halve the risk of death for lung cancer patients with a particular type of genetic mutation who have undergone surgery, according to much awaited clinical trial results.The drug is called osimertinib, which AstraZeneca Pharmaceuticals produces under the brand name Tagrisso.It has been used to treat later-stage lung cancer since the U.S. Food and Drug Administration granted it an accelerated approval in 2015.
#people #years #responsible #researchers #combination #participants #disease-control #lead-author #american-society #lung-cancer
[
add
]
[
|
|
...
]